

FORM PTO-1390(modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE
(REV 10-95)

ATTORNEY'S DOCKET NUMBER

29993

U.S. APPLICATION NO. (IF KNOWN), SEE 37 CFR

10/ 551 715

TRANSMITTAL LETTER TO THE UNITED STATES

DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING

A FILING UNDER 35 U.S.C., 371

INTERNATIONAL APPLICATION NO.

PCT/IL2004/000308

INTERNATIONAL FILING DATE

4 April 2004

PRIORITY DATE CLAIMED

4 April 2003

TITLE OF INVENTION

ANTIBODIES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME USEFUL FOR
INHIBITING ACTIVITY OF METALLOPROTEINS

APPLICANT(S) FOR DO/EO/US

(1) Irit SAGI; (2) Tamar DANON

Applicant herewith submits to the United States Designated/Elected Office (DO/EO.US) the following items and other information:

1. ☒ This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☐ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(3)(2)
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(3)(2).
7. ☒ A copy of the International Search Report (PCT/ISA/210).
8. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19(35 U.S.C. 371(c)(3)).
10. ☒ An unsigned oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
11. ☐ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 13 to 18 below concern document(s) of information included:

13. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☐ A FIRST preliminary amendment.
A SECOND or SUBSEQUENT preliminary amendment.
16. ☐ A substitute specification.
17. ☐ A change of power of attorney and/or address letter.
18. ☐ Certificate of Mailing by Express Mail
19. ☐ The sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing
20. ☒ Other items or information: **PCT REQUEST; PRELIMINARY AMENDMENT**
21. ☒ 57 pages of specification (including Abstract page)
22. ☒ 10 sheets of drawings
23. ☐ ___ pages of sequence listing
24. ☒ 67 total pages

U.S. APPLICATION NO. (IF KNOWN) - See 37 CFR

10/551715

INTERNATIONAL APPLICATION NO.
PCT/IL2004/000308

ATTORNEY'S DOCKET NUMBER
29993

THE FILING FEE HAS BEEN CALCULATED AS SHOWN BELOW:

FOR:	Column 1 No. FILED	Column 2 No. EXTRA	SMALL ENTITY		OTHER THAN A SMALL ENTITY	
			RATE	FEE	RATE	FEE
Basic National Stage Fee				\$ 150		\$ 300
National Stage Search Fee				\$ 250		\$ 500
National Stage Examination Fee				\$ 100		\$ 200
National Stage Application Size Fee (Per 50 Pages Over 100)			x \$ 125	\$	x \$250	\$
Multiple Dependent Claim			x \$ 180	\$	x \$ 360	\$
Total Claims*	57 - 20=	37	x \$ 25	\$ 925	x \$50	\$
Independent Claims*	10 - 3=	7	x \$100	\$ 700	x \$200	\$
* (If the difference in Column 1 is less than "0", enter "0" in Column 2)			TOTAL	<u>\$2125</u>	TOTAL	<u>\$</u>

- ☒ Please charge my deposit account No. 50-1407 in the amount of \$2,125.00.
A duplicate copy of this sheet is enclosed.
- ☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No 50-1407.
A duplicate copy of this sheet is enclosed.
- ☒ Any additional filing fees required under 37 CFR 1.16.
- ☒ Any patent application processing fees under 37 CFR 1.17.
- ☒ The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to deposit Account No. 50-1407.
A duplicate copy of this sheet is enclosed.
- ☒ Any patent application processing fees under 37 CFR 1.17.
- ☒ Any filing fees under 37 CFR 1.16 for presentation of extra claims.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Martin Moynihan
PRTSI, Inc.
P.O. Box 16446
Arlington, Virginia 22215
USA

Tel: (703) 598-7851 Fax: (703) 415-4864

Martin Moynihan
SIGNATURE

Martin Moynihan
NAME

40,338
REGISTRATION NUMBER

DATE